{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:51:09Z","timestamp":1786992669483,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["64787"],"award-info":[{"award-number":["64787"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI152183"],"award-info":[{"award-number":["R01AI152183"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203135\/Z\/16\/Z"],"award-info":[{"award-number":["203135\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["214321\/Z\/18\/Z"],"award-info":[{"award-number":["214321\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["TMA2017SF-1981"],"award-info":[{"award-number":["TMA2017SF-1981"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jid.2022.05.1059","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:16:55Z","timestamp":1654082215000},"page":"2920-2928.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["IFN-\u03b3 ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-6995","authenticated-orcid":false,"given":"Mireille","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8860-9635","authenticated-orcid":false,"given":"Phuti","family":"Choshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4005-8453","authenticated-orcid":false,"given":"Sarah","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6972-4718","authenticated-orcid":false,"given":"Tafadzwa","family":"Chimbetete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-891X","authenticated-orcid":false,"given":"Rhodine","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1196-4414","authenticated-orcid":false,"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7623-3383","authenticated-orcid":false,"given":"Elizabeth","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1281-1789","authenticated-orcid":false,"given":"Rannakoe","family":"Lehloenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-0723","authenticated-orcid":false,"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2022.05.1059_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2022.05.1059_bib2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.jid.2022.05.1059_bib3","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2022.05.1059_bib4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199306103282304","article-title":"Cutaneous disease and drug reactions in HIV infection","volume":"328","author":"Coopman","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.05.1059_bib5","article-title":"Dose dependent antimicrobial cellular cytotoxicity\u2014implications for ex\u00a0vivo diagnostics","volume":"12","author":"Copaescu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jid.2022.05.1059_bib6","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaip.2020.12.052","article-title":"The role of in\u00a0vivo and ex\u00a0vivo diagnostic tools in severe delayed immune-mediated adverse antibiotic drug reactions","volume":"9","author":"Copaescu","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jid.2022.05.1059_bib7","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","article-title":"The growing burden of tuberculosis: global trends and interactions with the HIV epidemic","volume":"163","author":"Corbett","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jid.2022.05.1059_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.preghy.2018.05.007","article-title":"Creating biobanks in low and middle-income countries to improve knowledge \u2013 the PREPARE initiative","volume":"13","author":"De Oliveira","year":"2018","journal-title":"Preg Hypertens"},{"key":"10.1016\/j.jid.2022.05.1059_bib9","first-page":"237","article-title":"Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report","volume":"2","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2022.05.1059_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0041-3879(80)90012-4","article-title":"Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report","volume":"61","year":"1980","journal-title":"Tubercle"},{"key":"10.1016\/j.jid.2022.05.1059_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2019.103937","article-title":"Evolution of rifampicin treatment for tuberculosis","volume":"74","author":"Grobbelaar","year":"2019","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jid.2022.05.1059_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000496389","article-title":"An update on adverse cutaneous drug reactions in HIV\/AIDS","volume":"6","author":"Hoosen","year":"2019","journal-title":"Dermatopathology (Basel)"},{"key":"10.1016\/j.jid.2022.05.1059_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4168\/aair.2021.13.2.245","article-title":"Severe cutaneous adverse reactions to anti-tuberculosis drugs in Korean patients","volume":"13","author":"Jin","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jid.2022.05.1059_bib14","doi-asserted-by":"crossref","unstructured":"Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998\/11\/03;53:536\u2013548.","DOI":"10.1136\/thx.53.7.536"},{"key":"10.1016\/j.jid.2022.05.1059_bib15","first-page":"264","article-title":"Drug reactions associated with antituberculosis drugs","volume":"28","author":"Kakande","year":"2015","journal-title":"Curr Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2022.05.1059_bib16","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jaad.2013.11.053","article-title":"Comments on: DRESS syndrome","volume":"71","author":"Kardaun","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.05.1059_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.05.1059_bib18","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/QAD.0000000000000345","article-title":"HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity","volume":"28","author":"Keane","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.jid.2022.05.1059_bib19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/icb.2011.34","article-title":"High-avidity, high-IFN\u03b3-producing CD8 T-cell responses following immune selection during HIV-1 infection","volume":"90","author":"Keane","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jid.2022.05.1059_bib20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/tmi.13275","article-title":"Cost of managing severe cutaneous adverse drug reactions to first-line tuberculosis therapy in South Africa","volume":"24","author":"Knight","year":"2019","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jid.2022.05.1059_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093543","article-title":"Factors associated with increased mortality in a predominantly HIV-infected population with stevens Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Knight","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2022.05.1059_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1586\/eri.12.13","article-title":"Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future","volume":"10","author":"Lehloenya","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jid.2022.05.1059_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaip.2020.08.012","article-title":"Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure","volume":"9","author":"Lehloenya","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jid.2022.05.1059_bib24","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jid.2022.05.1059_bib25","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.5588\/ijtld.10.0698","article-title":"Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions","volume":"15","author":"Lehloenya","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jid.2022.05.1059_bib26","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1093\/jac\/dks225","article-title":"Lichenoid drug reaction to antituberculosis drugs treated through with topical steroids and phototherapy","volume":"67","author":"Lehloenya","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jid.2022.05.1059_bib27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.5588\/ijtld.11.0187","article-title":"Multiple drug hypersensitivity reactions to anti-tuberculosis drugs: five cases in HIV-infected patients","volume":"16","author":"Lehloenya","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jid.2022.05.1059_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2172-9-9","article-title":"Precision and linearity targets for validation of an IFN\u03b3 ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides","volume":"9","author":"Maecker","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jid.2022.05.1059_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1258\/ijsa.2008.008361","article-title":"Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs","volume":"20","author":"Marks","year":"2009","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jid.2022.05.1059_bib30","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(19)30154-7","article-title":"Management of active tuberculosis in adults with HIV","volume":"6","author":"Meintjes","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jid.2022.05.1059_bib31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000362093","article-title":"Infrastructure and facilities for human biobanking in low- and middle-income countries: a situation analysis","volume":"81","author":"Mendy","year":"2014","journal-title":"Pathobiology"},{"key":"10.1016\/j.jid.2022.05.1059_bib32","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1016\/j.jaip.2021.07.051","article-title":"Pattern and impact of drug-induced liver injury in South African patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis and a high burden of HIV","volume":"9","author":"Nalitye Haitembu","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jid.2022.05.1059_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2022.05.1059_bib34","series-title":"The First National TB prevalence survey South Africa 2018 short report","year":"2021"},{"key":"10.1016\/j.jid.2022.05.1059_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaip.2013.11.005","article-title":"Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy","volume":"2","author":"Pavlos","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jid.2022.05.1059_bib36","first-page":"270","article-title":"A\u00a0South African multidisciplinary drug hypersensitivity clinic","volume":"28","author":"Peter","year":"2015","journal-title":"Curr Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2022.05.1059_bib37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjd.12109","article-title":"In\u00a0vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions","volume":"168","author":"Polak","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.05.1059_bib38","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.05.1059_bib39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1398-9995.2008.01674.x","article-title":"Detection and quantification of drug-specific T cells in penicillin allergy","volume":"64","author":"Rozieres","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jid.2022.05.1059_bib40","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the international Case Control Study on Severe cutaneous Adverse Reactions","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2022.05.1059_bib41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: comparison with case\u2013control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2022.05.1059_bib42","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","article-title":"Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis","volume":"9","author":"Schaberg","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jid.2022.05.1059_bib43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nprot.2009.7","article-title":"The role of IFN-gamma ELISPOT assay in HIV vaccine research","volume":"4","author":"Streeck","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jid.2022.05.1059_bib44","first-page":"143","article-title":"Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs","volume":"62","author":"Tan","year":"2007","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.jid.2022.05.1059_bib45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.det.2006.06.008","article-title":"Adverse cutaneous drug eruptions and HIV: a clinician's global perspective","volume":"24","author":"Todd","year":"2006","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jid.2022.05.1059_bib46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3201\/eid1304.051195","article-title":"Diagnosis of tuberculosis by an enzyme-linked immunospot assay for interferon-gamma","volume":"13","author":"Wang","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jid.2022.05.1059_bib48","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjd.14839","article-title":"Drug-specific CD4(+) T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome","volume":"176","author":"Ye","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.05.1059_bib49","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X22015007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X22015007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:52:22Z","timestamp":1762206742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X22015007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0022202X22015007"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2022.05.1059","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFN-\u03b3 ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2022.05.1059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}